We conducted a cross-sectional study to investigate the effects of the adenosine triphosphate-binding cassette transporter 1 (ABCA1) I883M and lipoprotein lipase (LPL) HindIII polymorphisms on lipid levels in patients with hyperlipidemia.A total of 533 patients were enrolled.
Hyperlipidemia altered the protein and mRNA expression levels of the key genes (SREBP-1c, ACC1, SREBP-2, HMGR, HMGS, CYP7A1, and ABCA1) in lipid metabolism and the treatment with Et-CAF (300mg/kg b. wt) reverted these levels similar to that observed with atorvastatin treated hyperlipidemic animals.
In conclusion, we provide additional evidence that the R219K polymorphism in the ABCA1 gene either directly or as a result of linkage disequilibrium with additional functional variant(s), has a protective effect against CHD and is associated with lower plasma triglycerides in sub-groups of patients with hyperlipidaemia.